ImmunoVaccine Technologies Inc. (IVT) has successfully scaled-up the manufacturing process for its vaccine platform, Vaccimax. The manufacturing development was performed by Dalton Pharma Services.

VacciMax is a vaccine-enhancement platform comprised of a special emulsion of liposomes, antigens, adjuvants and oil, according to IVT. To prepare VacciMax for human cancer clinical trials, IVT has been developing its platform to meet all regulatory requirements, including manufacturing in a GMP setting. Having successfully produced VacciMax at a commercially relevant batch size, the company plans to license the technology worldwide for the therapy and prevention of cancer and infectious diseases.

"We are pleased to collaborate with IVT and wish to congratulate the entire team on meeting such an important milestone. The successful scale-up of VacciMax was a direct result of the Dalton and IVT teams' strong technical capabilities and project management skills," remarked Peter Pekos, president and chief executive officer of Dalton Pharma Services.

IVT's testing verified that development batches produced at Dalton at an increasing scale retained their expected biological activity. Analytical testing also showed that the various elements of the platform are chemically stable. The latest batch produced at the 50-litre scale also met manufacturing and chemical specifications.